Companies: 10,795·Total market cap: $144.5T
Immunic, Inc.

Immunic, Inc.

IMUXNASDAQHealthcare● Active
$12.06
$-0.71(-5.56%)
Market Cap$119014580
P/E Ratio
52W High$15.77
52W Low$5.06
Overview

Immunic, Inc. (IMUX) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

imux · stock forecast · 12 analysts (3M) · FMP · updated Jun 9, 2026

Analyst Rating & Consensus

Based on 12 Wall Street analysts in the past 3 months

SellBuy

Buy

12 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
10
Hold
2
Sell
0
Strong Sell
0
Total: 12 · Buy rate: 83.3%

12-Month Price Target

High

$22.00

Consensus

$14.50

+20.2% upside

Low

$2.50

Median: $19 · Last Close: $12.06

The Immunic, Inc. (IMUX) analyst consensus is Buy, based on ratings from 12 Wall Street analysts over the past 3 months. The average 12-month IMUX price target is $14.50, representing +20.2% upside from the current price of $12.06.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $15 (20.2%)

Consensus Target

$14.50

20.2% upside

High Target

$22

82.4%

Low Target

$2.5

-79.3%

Current Price

$12.06

as of today

Based on analyst price targets, the IMUX stock price prediction for the next 12 months ranges from $2.5 to $22. The consensus IMUX price forecast of $14.50 implies 20.2% upside from the current price of $12.06.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-10$12.392.76%

1-day model range: $12.27–$12.51. Peak: $12.51 (+2.76%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$8-35.1%
2028$6-46.4%
2029$6-51.1%
2030$6-53.3%
2031-54.3%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

NEUTRAL

Based on 14 technical indicators

50%7%43%
7Buy
1Neutral
6Sell
RSI (14)52.7Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · IMUX · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$13.61SELL
MA 10$14.01SELL
MA 20$13.09SELL
MA 50$11.69BUY
MA 100$10.46BUY
MA 200$9.03BUY
Current $IMUX · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$13.26SELL
EMA 10$13.46SELL
EMA 20$13.05SELL
EMA 50$11.99BUY
EMA 100$10.88BUY
EMA 200$10.02BUY
Current $IMUX · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
B. Riley Securities2026-05-22
Maintains
BuyBuy
HC Wainwright & Co.2026-04-30
Maintains
BuyBuy
D. Boral Capital2026-04-15
Downgrade ↓
BuyHold
HC Wainwright & Co.2026-03-02
Maintains
BuyBuy
D. Boral Capital2026-02-13
Maintains
BuyBuy
HC Wainwright & Co.2026-02-09
Maintains
BuyBuy
D. Boral Capital2026-01-07
Maintains
BuyBuy
HC Wainwright & Co.2025-11-14
Maintains
BuyBuy
D. Boral Capital2025-11-13
Maintains
BuyBuy
HC Wainwright & Co.2025-09-26
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Immunic, Inc. (IMUX) stock. Of the recent 48 rating actions, 0 were upgrades and 2 were downgrades. 12 analysts currently cover IMUX.

Analyst Recommendation Trends

Buy ratings211
Hold ratings00
Sell ratings00

IMUX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$13M

↓ 79.2% YoY

Revenue Next Year

$13M

↑ 0.0% YoY

EPS This Year

$-4.38

EPS Next Year

$-3.55

↓ 19.1% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast IMUX EPS of $-4.38 for the current fiscal year, based on estimates from 8 analysts. The IMUX revenue forecast is $13M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The IMUX stock forecast is supported by two independent data sources: analyst consensus ratings from 12 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IMUX price target is $14.50 (+20.2% upside), with an analyst consensus of Buy.

The IMUX short-term stock prediction for tomorrow is $12.39 (+2.76%). The IMUX stock price prediction for 2027 estimates an average of $8. The IMUX stock prediction for 2030 projects a range of $5–$6.

Immunic, Inc. trades on NASDAQ under the ticker IMUX. The IMUX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 83% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

IMUX forecast · 8 questions

According to 12 Wall Street analysts, the average 12-month IMUX price target is $14.50, with a high forecast of $22.00 and a low of $2.50. The median price target is shown in the chart above when available. This implies +20.2% potential upside from the current price of $12.06.

IMUX price targetWhat is IMUX price targetIMUX analyst price targetIMUX 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.